张同泰品牌怎么样 申请店铺

我要投票 张同泰在中医保健行业中的票数:210 更新时间:2025-04-02
张同泰是哪个国家的品牌?「张同泰」是 杭州张同泰药业有限公司 旗下著名品牌。该品牌发源于浙江,由创始人潘慧芳在2009期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力张同泰品牌出海!通过在本页面挂载张同泰品牌的产品链接和联系邮箱,可以提高张同泰产品曝光!跨境电商爆单神器,目前只要100元/年哦~

张同泰怎么样

张同泰,是清朝年间杭州老商号,始创于1805年,比胡庆余堂还要早70年左右,以其道地的中药材在江浙一带很有名气,2000年被列入杭州市文物保护单位。

创始人张梅,浙江慈溪人。清嘉庆五年(1800年)在杭州新宫桥下开设茂昌药号。嘉庆十年,盘进沈同泰药号而取名为张同泰。张同泰生产各种丸散,膏丹,药酒,在杭嘉湖一带享有盛名,和胡庆余堂,叶种德堂齐名号杭州三大药堂。民国元年,药店经大规模翻建后,新屋落成,重建石墙门,上刻“万象”商标。“张同泰”镀金大字熠熠生辉,大门两旁悬挂“张同泰道地药材”铜牌,自制传统成药360余种。首批进入商务部“老字号企业”。

杭州华东大药房连锁有限公司是杭州主要的大型医药零售连锁企业之一,隶属华东医药股份有限公司,具有独立法人地位。法人代表李邦良为全国十届人大代表、华东医药股份有限公司董事长。总部设在南宋御街中山中路323号,注册资本1500万元,经营中西成药,中药材,饮片配方,医疗器械等近2万余个品种,2008年销售1.08亿元。

公司是GSP质量认证企业,实行先进的计算机信息系统管理。现有门店22家,一个中医门诊部。全部列入市医保定点药店同时拥有五家省医保定点药店。门店中既有久负盛名的中华老字号,又有新型医药卖场,覆盖杭州主要城区,在市民中享有较高的信誉和知名度。

Zhang Tongtai, an old business name in Hangzhou during the Qing Dynasty, was founded in 1805, about 70 years earlier than Hu qingyutang. It is famous for its authentic Chinese medicinal materials in Jiangsu and Zhejiang. It was listed as a cultural relic protection unit in Hangzhou in 2000. Founder Zhang Mei, from Cixi, Zhejiang Province. In the fifth year of Jiaqing Dynasty (1800), Maochang medicine number was opened under the new palace bridge in Hangzhou. In the 10th year of Jiaqing, Pan Jin was named Zhang Tongtai after Shen Tongtai. Zhang Tongtai produces all kinds of pills, ointments and medicinal wine. He is famous in Hangjiahu area. He is as famous as Hu qingyutang and ye Zhongde Tang as the three medicine halls in Hangzhou. In the first year of the Republic of China, after the large-scale renovation of drugstores, the new house was completed, the stone wall door was rebuilt, and the "Vientiane" trademark was engraved on it. "Zhang Tongtai" gilded big characters are shining, and "Zhang Tongtai genuine herbs" bronze medals are hung on both sides of the gate, with more than 360 kinds of self-made traditional medicines. It is one of the first batch to enter the "time-honored enterprises" of the Ministry of Commerce. Hangzhou Huadong pharmacy chain Co., Ltd. is one of the major large-scale pharmaceutical retail chain enterprises in Hangzhou. It is subordinate to Huadong Pharmaceutical Co., Ltd. and has an independent legal person status. Li Bangliang, the legal representative, is the representative of the 10th National People's Congress and the chairman of East China Pharmaceutical Co., Ltd. Headquartered in No. 323, Zhongshan Middle Road, Yujie street, Southern Song Dynasty, with a registered capital of 15 million yuan, the company operates nearly 20000 varieties of Chinese and Western patent medicines, Chinese herbal medicines, decoction pieces, medical devices, etc., with a sales volume of 108 million yuan in 2008. GSP quality certification company, the implementation of advanced computer information system management. There are 22 stores and one TCM clinic. All of them are listed in the designated pharmacies of municipal medical insurance and have five designated pharmacies of provincial medical insurance at the same time. In the store, there are not only famous Chinese time-honored brands, but also new medicine stores, covering the main urban areas of Hangzhou, enjoying high reputation and popularity among the citizens.

本文链接: https://brand.waitui.com/30a3c39cf.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

今年一季度A股新开户747万户,同比增长31.74%

36氪获悉,4月2日,上交所披露,今年3月A股新开户数据306.55万户,环比继续快速增长。数据显示,今年1月、2月和3月A股新开户数分别为157万户、283.59万户和306.55万户。今年3月新增开户数306.55万户,较2024年3月新开户数242万户同比增长26.67%。

4分钟前

国信证券:获批发行不超200亿元永续次级债券

36氪获悉,国信证券公告,近日收到中国证监会出具的批复,同意公司向专业投资者公开发行面值总额不超过200亿元永续次级债券的注册申请。批复自同意注册之日起24个月内有效,公司在注册有效期内可以分期发行永续次级公司债券。公司将按照有关法律法规和上述批复文件要求及公司股东大会的授权办理永续次级债券发行的相关事宜,并及时履行信息披露义务。

4分钟前

华为哈勃入股成都芯曌科技,后者含电子专用材料研发等业务

36氪获悉,天眼查App显示,近日,成都芯曌科技有限公司发生工商变更,新增华为旗下深圳哈勃科技投资合伙企业(有限合伙)为股东,注册资本由6213万人民币增至约7020万人民币,同时,部分高管发生变更。成都芯曌科技有限公司成立于2019年10月,法定代表人为朱荣,经营范围含电子专用材料研发、电子专用材料制造、电子专用材料销售、集成电路设计、电子元器件制造等。股东信息显示,该公司现由成都大超科技有限公司、朱荣及上述新增股东共同持股。

4分钟前

恒润股份:公司基本面未发生重大变化

36氪获悉,恒润股份发布股票交易风险提示公告,公司股票股价短期涨幅较大,存在一定风险。公司基本面未发生重大变化,也不存在应披露而未披露的重大信息。敬请广大投资者注意二级市场交易风险,理性决策,审慎投资。

5分钟前

立讯精密被曝正考虑赴港上市?官方不予置评

日前,有消息称,有知情人士透露立讯精密考虑今年在香港上市,目前正与投行商讨赴港上市事宜,初步预计融资规模为20亿至30亿美元。不过,知情人士也提醒,立讯精密赴港上市规模尚未最终确定,将取决于市场情况。对此,立讯精密表示,不予置评。

5分钟前

本页详细列出关于阿炳的品牌信息,含品牌所属公司介绍,阿炳所处行业的品牌地位及优势。
咨询